MedTrace Logo

N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia

NCT01885338 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2015-06-04

No results posted yet for this study

Summary

This study will evaluate the effect of the dietary supplement N-acetylcysteine (NAC) on electrophysiologic (EEG) markers related to cognition, as well as performance on psychological tests measuring cognition. The primary hypothesis is that participants treated with NAC will show improvements in cognitive function, as measured by EEG and performance-based tests.

Conditions

Interventions

DRUG

N-acetylcysteine (NAC)

DRUG

Inactive placebo capsule

Sponsors & Collaborators

  • VISN 22 Mental Illness Research, Education, and Clinical Center

    collaborator FED

  • American Psychiatric Foundation

    collaborator UNKNOWN

  • VA Greater Los Angeles Healthcare System

    lead FED

Principal Investigators

  • Stephen R Marder, M.D. · VA Greater Los Angeles

  • Michael C Davis, M.D., Ph.D. · VA Greater Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01885338 on ClinicalTrials.gov